Mystic Asset Management Inc. Has $2.61 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Mystic Asset Management Inc. grew its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 1.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 313,347 shares of the company’s stock after buying an additional 5,900 shares during the quarter. Mystic Asset Management Inc.’s holdings in Zevra Therapeutics were worth $2,613,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. FMR LLC raised its position in Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after buying an additional 2,312,384 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Zevra Therapeutics by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after acquiring an additional 129,600 shares in the last quarter. State Street Corp raised its holdings in shares of Zevra Therapeutics by 7.4% in the third quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after purchasing an additional 52,966 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $4,858,000. Finally, Vestal Point Capital LP bought a new stake in shares of Zevra Therapeutics in the third quarter worth $3,644,000. 35.03% of the stock is currently owned by institutional investors.

Insider Activity

In other Zevra Therapeutics news, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now owns 29,486 shares in the company, valued at $231,759.96. This trade represents a 26.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the transaction, the chief executive officer now owns 222,060 shares in the company, valued at $1,745,391.60. The trade was a 21.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 85,773 shares of company stock valued at $674,176 over the last ninety days. 2.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Guggenheim increased their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Finally, Canaccord Genuity Group upped their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and an average price target of $22.14.

Zevra Therapeutics Stock Performance

ZVRA opened at $8.35 on Tuesday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The business has a 50 day moving average of $7.92 and a 200-day moving average of $8.17. The stock has a market cap of $451.87 million, a price-to-earnings ratio of -4.24 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. On average, equities research analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.